Trial Profile
Efficacy and safety of Anlotinib plus Epirubicin civ followed by Anlotinib sequential therapy in the first-line chemotherapy for advanced soft tissue sarcoma (STS): A single-arm phase 2 clinical trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Epirubicin (Primary)
- Indications Dermatofibrosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 13 Oct 2022 Results published in the Clinical Cancer Research
- 22 Jul 2021 Status changed from not yet recruiting to completed, as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology